Dr Hans M Zinnecker, MD in Holdrege, NE - Surgery

Dr Hans M Zinnecker, MD is a Surgery physician based in Holdrege, Nebraska. Dr Hans M Zinnecker is licensed to practice in Nebraska (license number 17941) and his current practice location is 1215 Tibbals St, Holdrege, Nebraska. He can be reached at his office (for appointments etc.) via phone at (507) 454-3680.

NPI number for Dr Hans M Zinnecker is 1427028737 and his current mailing address is 1215 Tibbals St, Holdrege, Nebraska. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1427028737.

Contact Information

	Dr Hans M Zinnecker, MD
	1215 Tibbals St, Holdrege, NE 68949-1255
	(507) 454-3680
	Not Available

Physician's Profile

Full Name	Dr Hans M Zinnecker
Gender	Male
Speciality	Surgery
Location	1215 Tibbals St, Holdrege, Nebraska
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1427028737
Provider Enumeration Date: 01/26/2006
Last Update Date: 09/15/2014

Medical Identifiers

Medical identifiers for Dr Hans M Zinnecker such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1427028737	NPI	-	NPPES
0273086	Medicaid	IA

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208600000X	Surgery	24592 (Iowa)	Secondary
208600000X	Surgery	51554 (Minnesota)	Secondary
208600000X	Surgery	17941 (Nebraska)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Hans M Zinnecker is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Hans M Zinnecker, MD 1215 Tibbals St, Holdrege, NE 68949-1255 Ph: (507) 454-3680	Dr Hans M Zinnecker, MD 1215 Tibbals St, Holdrege, NE 68949-1255 Ph: (507) 454-3680

News Archive

Mount Sinai launches clinical trial to test effectiveness of ticagrelor drug in treating coronary stent patients

The Icahn School of Medicine at Mount Sinai has launched an international clinical trial called TWILIGHT to test the safety and effectiveness of treating coronary stent patients with the anti-clotting medication ticagrelor alone, instead of combining it with aspirin, which is the current standard of care. Researchers will analyze the potential benefits of administering ticagrelor to reduce clotting while at the same time reducing the risk of bleeding associated with the use of both medications.

Obesity associated with hypothalamic injury

The number of people who suffer from one or more of the adverse complications of obesity, including type 2 diabetes and heart disease is rapidly increasing. Thus far, drugs designed to treat obesity have shown limited efficacy and have been associated with serious side effects.

Rising triglyceride levels may be behind rising rates of obesity

A new 30-year analysis of the National Health and Nutrition Examination Survey (NHANES) database conducted by the National Lipid Association (NLA) indicates that while Americans are doing a better job of managing LDL or "bad" cholesterol, the percentage of adults with high triglycerides, a blood fat linked to heart disease, has doubled, leaving many people at risk for potentially life-threatening events such as heart attack or stroke.

Florida budget officials tap into tobacco endowment fund to provide health care for low-income, severely ill residents

Florida state budget negotiators on Wednesday approved a measure to shift $300 million from the Lawton Chiles Tobacco Endowment for Children and Elders to preserve social and health care services for about 40,000 residents in state Medically Needy and the Medicaid Aged-and-Disabled programs, the Miami Herald reports.

Transcriptomics identifies possible COVID-19 therapies

By using a diverse set of transcriptomic SARS-CoV-2 signatures, US researchers put to use their previously developed drug repositioning pipeline to pinpoint potential drug candidates for the treatment of coronavirus disease (COVID-19). The study is currently available on bioRxiv preprint server.

Dr Hans M Zinnecker, MD - Surgery in Holdrege, NE